Novel clinical strategies for the treatment of pancreatic carcinoma
- 1 January 2001
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 7 (1) , 30-37
- https://doi.org/10.1016/s1471-4914(00)01865-7
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Topoisomerase I Poisons and Suppressors as Anticancer DrugsCurrent Medicinal Chemistry, 2000
- Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming unitsAnti-Cancer Drugs, 1999
- Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF)Biochemical Pharmacology, 1999
- An investigational new drug treatment program for patients with gemcitabineCancer, 1999
- Evaluation of Pancreatic Proteolytic Enzyme Treatment of Adenocarcinoma of the Pancreas, With Nutrition and Detoxification SupportNutrition and Cancer, 1999
- Cancer statistics, 1998CA: A Cancer Journal for Clinicians, 1998
- Alkyl Esters of Camptothecin and 9-Nitrocamptothecin: Synthesis, in Vitro Pharmacokinetics, Toxicity, and Antitumor ActivityJournal of Medicinal Chemistry, 1998
- DX-8951F, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variantInternational Journal of Cancer, 1997
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agentsInvestigational New Drugs, 1996